Recruiting Clinical Trials

Displaying 11 - 20 of 242 result(s)
Study Title Condition Phase Location
International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours Neuroendocrine Tumors Not Given
  • Country: 
    United States
  • Country: 
    France
  • Country: 
    Portugal
  • Country: 
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive ... Sickle Cell Disease (SCD) Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    Brazil
  • Country: 
A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension Multiple Sclerosis (MS) Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS Multiple Sclerosis Phase 3
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Italy
  • Country: 
Randomized, Single-dose, Open-label, Two-part, Two-period, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric With an Adult Formulation of Branaplam and to Investigate the Adult Formulation in Fed and Fasted St ... Healthy Volunteers Phase 1
  • Country: 
    United Kingdom
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Phase 2
  • Country: 
    United States
  • Country: 
    Belgium
  • Country: 
    France
  • Country: 
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer) Non-small Cell Lung Cancer Not Given
  • Country: 
    Japan
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygou ... Familial Hypercholesterolemia - Heterozygous Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Brazil
  • Country: 
A Phase 2 Interventional, Multicenter, Randomized, Open-label Study in Three Age-descending Cohorts to Evaluate Efficacy, Safety and Tolerability of KAF156 and Lumefantrine-SDF Combination, Under Fasted or Fed Conditions, in the Treatment of Acute Un ... Uncomplicated Plasmodium Falciparum Malaria Phase 2
  • Country: 
    Burkina Faso
  • Country: 
    Gabon
  • Country: 
    Mali